- Eisbach Bio GmbH
- Am Klopferspitz 19
- 82152 Planegg/Martinsried
- Deutschland
- Phone: +49 (0)89/21 53 79 0-0
- oib.hcabsie@ofni
Eisbach Bio
Dr. Adrian Schomburg
CEO & Founder
About Eisbach Bio
Some of the most devastating tumors develop due to the loss of function in tumor suppressor genes. These tumors are often incredibly difficult to treat, and in most cases, no targeted treatments exist. However, significant advances in tumor genome sequencing have revealed the “Achilles’ heels” of these tumors, including molecular motors that drive structural rearrangements within the tumor genome. Eisbach Bio has developed a method to directly combat these tumors using our proprietary epigenetic key technologies. Leveraging our unique screening and cell platform technology, we are developing first-class drugs that correct these disruptive changes in tumors. We can achieve this in a highly specific manner that spares healthy cells. In 2024, Eisbach will initiate the clinical trial of EIS-12656, our leading oncology program, at the MD Anderson Cancer Center at the University of Texas in Houston to evaluate the safety, tolerability, and efficacy of the small molecule.
What is your motivation?
We are a bold, curious, and strong team dedicated to transforming patients’ lives and be stewards of our community. Eisbach aims to create groundbreaking therapeutics for treating incurable cancers based on the principle of synthetic lethality. We are committed to making cancers with tumor suppressor deficiencies treatable and will harness our latest scientific discoveries to pioneer new drugs and improve the lives of many patients for whom there is currently no cure.
“The IZB provides our team with a perfect environment that is highly conducive to our innovative projects and research activities. We are grateful to be part of this community.”
Dr. Adrian Schomburg
CEO & Founder
Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-off of the Biomedical Center Munich. We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes. Thanks to a unique screening approach, Eisbach will establish cures for tumors that currently have no viable therapeutic option. In combination with existing drugs, our molecules will also make current therapies much more effective and greatly reduce their negative side-effects. By inhibiting genome evolution, we will furthermore increase the number of patients that can benefit from cancer immunotherapy. Eisbach will beat cancer at its own game.